Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The association between the IGF-I axis, thyroid hormones and cortical bone in patients with mild primary hyperparathyroidism.

Simintiriadis D, Bondeson AG, Bondeson L, Svensson J, Almqvist EG.

Scand J Clin Lab Invest. 2013 Feb;73(1):34-41. doi: 10.3109/00365513.2012.733409. Epub 2012 Oct 25.

PMID:
23098341
2.
3.

Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis.

Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ.

J Bone Miner Res. 1999 Dec;14(12):2150-8.

4.

Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men.

Gillberg P, Olofsson H, Mallmin H, Blum WF, Ljunghall S, Nilsson AG.

Calcif Tissue Int. 2002 Jan;70(1):22-9. Epub 2001 Dec 21.

PMID:
11907704
6.

Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study.

Szulc P, Joly-Pharaboz MO, Marchand F, Delmas PD.

Calcif Tissue Int. 2004 Apr;74(4):322-9.

PMID:
15255068
7.

Growth hormone, insulin growth factor-1, and igf binding protein-3 axis relationship with bone mineral density among healthy men.

Krassas GE, Papadopoulou P, Koliakos G, Konstantinidis T, Kalothetou K.

Arch Androl. 2003 May-Jun;49(3):191-9.

PMID:
12746097
9.

Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism.

Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L.

Clin Endocrinol (Oxf). 2008 May;68(5):707-15. Epub 2007 Nov 2.

PMID:
17980013
10.

The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy.

Alonso S, Ferrero E, Donat M, Martínez G, Vargas C, Hidalgo M, Moreno E.

J Endocrinol Invest. 2012 Jul;35(7):640-4. doi: 10.3275/7923. Epub 2011 Sep 23.

PMID:
21946027
11.

Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.

Lu KC, Ma WY, Yu JC, Wu CC, Chu P.

Clin Endocrinol (Oxf). 2012 May;76(5):634-42. doi: 10.1111/j.1365-2265.2011.04265.x.

PMID:
22007930
12.

Age, body mass index, current smoking history, and serum insulin-like growth factor-I levels associated with bone mineral density in middle-aged Korean men.

Rhee EJ, Oh KW, Lee WY, Kim SW, Oh ES, Baek KH, Kang MI, Park CY, Choi MG, Yoo HJ, Park SW.

J Bone Miner Metab. 2004;22(4):392-8.

PMID:
15221500
13.

Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism.

Lakatos P, Foldes J, Nagy Z, Takacs I, Speer G, Horvath C, Mohan S, Baylink DJ, Stern PH.

Thyroid. 2000 May;10(5):417-23.

PMID:
10884189
14.

Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study.

Sääf M, Hilding A, Thorën M, Troell S, Hall K.

Eur J Endocrinol. 1999 May;140(5):390-9.

15.

Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.

Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S.

J Bone Miner Res. 1998 May;13(5):891-9.

16.

Concentration of insulin-like growth factor (IGF)-I in iliac crest bone matrix in premenopausal women with idiopathic osteoporosis.

Pepene CE, Seck T, Diel I, Minne HW, Ziegler R, Pfeilschifter J.

Exp Clin Endocrinol Diabetes. 2004 Jan;112(1):38-43.

PMID:
14758570
17.

Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men.

Johansson AG, Forslund A, Hambraeus L, Blum WF, Ljunghall S.

J Bone Miner Res. 1994 Jun;9(6):915-21.

PMID:
7521562
18.

Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism.

Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A, Cormier C.

Osteoporos Int. 2014 Jul;25(7):1963-8. doi: 10.1007/s00198-014-2689-2. Epub 2014 Mar 28.

PMID:
24676846
19.

Bone metabolism in patients with primary hyperparathyroidism before and after surgery.

Kerschan-Schindl K, Riss P, Krestan C, Rauner M, Bieglmayer C, Gleiss A, Fialka-Moser V, Niederle B, Pietschmann P.

Horm Metab Res. 2012 Jun;44(6):476-81. doi: 10.1055/s-0032-1308998. Epub 2012 Apr 11.

PMID:
22495973
20.

Association between thyroid hormone levels, the number of circulating osteoprogenitor cells, and bone mineral density in euthyroid postmenopausal women.

Pirro M, Manfredelli MR, Scarponi AM, Lupattelli G, Bagaglia F, Melis F, Mannarino E.

Metabolism. 2012 Apr;61(4):569-76. doi: 10.1016/j.metabol.2011.09.006. Epub 2011 Nov 9.

PMID:
22075271
Items per page

Supplemental Content

Write to the Help Desk